240400-95-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
6-Bromo-1,4-dichlorophthalazine is utilized as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, playing a crucial role in the development of new drugs and pesticides. Its unique chemical structure allows for the creation of a wide range of compounds with different therapeutic and pesticidal properties.
Used as an Antibacterial and Antifungal Agent:
6-Bromo-1,4-dichlorophthalazine has been studied for its potential use as an antibacterial and antifungal agent. Its chemical composition and properties enable it to target and inhibit the growth of various bacteria and fungi, making it a promising candidate for the development of new antimicrobial agents.
Used as a Precursor in Organic Synthesis:
Due to its versatile chemical structure, 6-Bromo-1,4-dichlorophthalazine serves as a valuable precursor in the synthesis of various organic compounds. It can be further modified and functionalized to produce a range of molecules with different properties and applications, contributing to the advancement of organic chemistry.

Upstream product

• 240400-94-6 6-bromo-1,4-phthalazinedione 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 86-90-8 4-bromophthalic anhydride 
• 76240-49-8 6-bromo-2,3-dihydrophthalazine-1,4-dione 

Downstream Products

• 240400-93-5 6-Bromo-1-chloro-4-[(3-chloro-4-methoxybenzyl)amino]phthalazine 
• 1028338-57-9 7-bromo-4-chloro-2H-phthalazin-1-one 
• 1028338-59-1 6-bromo-4-chlorophthalazin-1(2H)-one 

Relevant academic research and scientific papers

SOS1 INHIBITORS

The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

N -Chlorinative Ring Contraction of 1,4-Dimethoxyphthalazines via a Bicyclization/Ring-Opening Mechanism

An unprecedented N -chlorinative ring contraction of 1,2-diazines was discovered and investigated with an electrophilic chlorinating reagent, trichloroisocyanuric acid (TCICA). Through optimization and mechanistic analysis, the assisting role of n -Bu 4NCl as an exogenous nucleophile was identified, and the optimized reaction conditions were applied to a range of 1,4-dimethoxyphthalazine derivatives. Also, an improvement of overall efficiency was demonstrated by the use of a labile O -silyl group. A bicyclization/ring-opening mechanism, inspired by the Favorskii rearrangement, was proposed and supported by the DFT calculations. Furthermore, the efforts on scope expansion as well as the evaluation of other electrophilic promoters revealed that the newly developed ring contraction reactivity is a unique characteristic of 1,4-dimethoxyphthalazine scaffold and TCICA.

MTA-Cooperative PRMT5 Inhibitors

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

SOS1 INHIBITORS

The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

N-Chlorination-induced, oxidative ring contraction of 1,4-dimethoxyphthalazines

A rarely explored oxidative ring contraction of electron-rich 1,2-diazine is described. Upon treatment with an electrophilic chlorinating reagent (TCICA), 1,4-dimethoxyphthalazines undergo an N-chlorination-induced ring contraction that is accompanied by the loss of one nitrogen atom. The scope of this unusual reactivity was examined with a range of 1,4-dimethoxyphthalazine derivatives. In addition, a mechanism proceeding via a bicyclic species was proposed on the basis of an isolated reaction intermediate and DFT calculations.

Macrocyclic Compounds As Antiviral Agents

A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):

SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS

The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.

Phthalazine derivatives and remedies for erectile dysfunction

The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1and R2are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1is a chlorine atom, R2is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.